[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

The Short Bowel Syndrome‐Quality of Life (SBS‐QoL™) scale is a reliable, sensitive instrument developed to measure and evaluate the QoL of adult patients with SBS. There has been a focus on assessment of QoL in the treatment of patients with SBS in Japan; however, a Japanese‐language SBS‐specific scale is not available. We aimed to create a Japanese version of the SBS‐QoL™ (©2023 Takeda Pharmaceutical Company Limited) based on the original English version.
A provisional Japanese version was created in accordance with the guidelines of the International Society for Pharmacoeconomics and Outcomes Research Task Force, through forward translation, adjustment, and back-translation. Cognitive debriefing using the provisional Japanese version was conducted with six Japanese patients with SBS; based on the results, the Japanese wording was evaluated and adjusted, and the final Japanese version was created. The Japanese version of the SBS‐QoL™, which has confirmed linguistic equivalence with the English version, is expected to assist in the treatment of patients with SBS, with the goal of improving their QoL.

View full abstract

Aim：The aim of the present study was to evaluate serum zinc levels in patients with gastric cancer.
Methods：We enrolled 702 patients who had been diagnosed with gastric cancer at Kochi Medical School between 2013 and 2021. Clinical data were obtained to investigate associations between clinicopathological features, including nutritional indicators, and serum zinc levels. Serum zinc deficiency was defined as serum zinc level <80 μg/dL.
Results：The median zinc level of the 702 patients was 73 μg/dL (range, 13.5–152.0 μg/dL). Serum zinc deficiency was present in 68.1% of patients. Median age was significantly higher in the low zinc level group than in the normal group (71 years old vs. 67 years old, P < 0.001). Albumin was significantly lower in the low zinc level group than in the normal group (3.9 g/dL vs. 4.2 g/dL, P <0.001). Serum zinc levels showed a significant positive correlation with serum albumin (r = 0.528). Median serum zinc level was significantly lower in patients who received chemotherapy after gastrectomy than those who did not receive chemotherapy (72 vs. 76 μg/dL, P <0.001). Median serum zinc level was significantly lower at 3 to 6 months after gastrectomy than at 1 month or 1 to 3 months after gastrectomy (68 μg/dL vs. 77 μg/dL, P < 0.001;68 μg/dL vs. 73 μg/dL, P = 0.024; respectively). Median serum zinc level was also significantly higher at over 12 months after gastrectomy than at 3 to 6 months after gastrectomy (74 μg/dL vs. 68 μg/dL, P = 0.010).
Conclusions：Serum zinc deficiency was found in 68.1% of patients with gastric cancer and was highly correlated with serum albumin and age. Serum zinc levels reached the lowest value at 3 to 6 months after gastrectomy. It is important for physicians to take zinc supplementation into consideration when they manage patients with gastric cancer.

View full abstract

Objective：To clarify the usefulness of anamorelin in clinical practice.
Subjects and Methods：We reviewed patient background, efficacy, adverse events, duration of treatment, and clinical course in 13 cases of anamorelin treatment (12 non‐small cell lung cancer, and one thymoma) in our department retrospectively.
Results：Median age was 78 years. BMI was <18.5 in nine cases. Weight loss was>10% in nine cases. ECOG PS was 2 in eight cases. Anorexia G2 was found in eight cases. Fatigue or malaise was present in all 13 cases, and generalized muscle weakness in 11 cases. Eight patients were receiving cancer drug therapy, and five were receiving BSC. Oral nutritional supplements were administered in five cases, opioids in three cases, and prednisolone in three cases. The effect of anamorelin on appetite according to the attending physician’s interview was effective in 11 cases and ineffective in two cases. Appetite increased within 3 days of initiation of treatment in 7 of the 11 effective cases and within 7 days in 10 of these cases. Duration of treatment ranged from 11 to 177 days (median 62) in the 11 effective cases. Two invalid patients received the drug for 7 and 27 days. Adverse events were CTCAE G1 nausea in one patient, G1 QTc prolongation in one patient, and G2 heart failure in one patient.
Conclusion：The usefulness of anamorelin in patients with cancer cachexia, such as non‐small cell lung cancer, was confirmed in our clinical study.

View full abstract